



ADULT MEDICATION GUIDELINE	
TRANEXAMIC ACID	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding
----------------------	--------------------------------	----------------------------	---

Restrictions

[Formulary: Unrestricted](#)

[HIGH RISK Medication](#) 

Medication Class

Antifibrolytic

Presentation

Ampoule: 1g/10mL (100mg/mL)

Tablets: 500mg

Storage

Store at room temperature, below 25°C

Ampoule: Store at room temperature, below 25°C. Protect from light

Dose

Schedule 8 Medication

Haemorrhage (for short term use)

Oral:

1 - 1.5g two to four times a day

IV:

Consult haematologist. 1g over 10 minutes. A second dose may be required.

Hereditary Angioedema**Oral:**

1 - 1.5g two to three times a day either continuously or intermittently if aware of an imminent attack

Menorrhagia**Oral:**

1 - 1.5g three to four times a day for 3 to 5 days during menses

Myomectomy**IV:**

10mg/kg (Maximum 1g) loading dose over 10 mins followed by infusion of 1mg/kg/min. Cease at the end of surgery.

Administration**Oral**

Take with or without food

IV injection

Inject slowly at a rate of 50mg/minute (0.5mL/min of undiluted solution)

IV infusion

Step 1 Dilution: Dilute 1g in 100mL in Glucose 5% or NaCl 0.9% to make a concentration of 10mg/mL

Step 2 Administration: Infuse at a rate of 5ml/minute. Maximum infusion rate is 100mg/minute

Monitoring

Manufacturer recommends dose reduction in renal impairment

Pregnancy

1st Trimester: Monitoring required

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Considered safe to use

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

[Critical Bleeding – Rotem Algorithm \(Intranet\)](#)

[Postpartum Complications \(Intranet\)](#)

[Contraception](#)

[Gynaecology \(non-oncology\)](#)

WNHS Pharmaceutical and Medicines Management Guidelines:

[High Risk medicines \(Intranet\)](#)

[Medication Administration \(Intranet\)](#)









References

Australian Medicines Handbook. Tranexamic acid. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Feb 10]. Available from: <https://amhonline.amh.net.au/>

Therapeutic Guidelines. Heavy menstrual bleeding (menorrhagia). In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2017 [cited 2022 Feb 10]. Available from: <https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess>

The Royal Women's Hospital. Tranexamic Acid. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 Feb 10]. Available from: <https://thewomenspbmg.org.au/>

Society of Hospital Pharmacists of Australia. Tranexamic acid. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2022 Feb 10]. Available from; <http://aidh.hcn.com.au>

Keywords	Tranexamic acid, cyclokapron, haemorrhage, menorrhagia, myomectomy, hereditary angioedema, antifibrotic, plasmin inhibitor, blood loss, bleeding, plasminogen, von Willebrand, Aminocaproic acid, fibrin, clot formation, TXA,				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	12/2014	Last Reviewed:	Feb 2022	Review Date:	Feb 2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/03/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.